CAR-T Cell Therapy Targeting BCMA Is Effective for R/R Multiple Myeloma, Independent of ECOG Performance Status
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
American Journal of Hematology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
CAR-T cell therapy targeting B cell maturation antigen is effective for relapsed/refractory multiple myeloma, including cases with poor performance status
Am. J. Hematol 2022 Apr 29;[EPub Ahead of Print], J Du, R Wei, S Jiang, H Jiang, L Li, W Qiang, H He, L Shi, Q Ma, K Yu, X Zhang, H Ding, X Sun, F Xiang, L Zhu, Z Cheng, W FuFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.